{"id":1012,"date":"2026-03-02T20:24:05","date_gmt":"2026-03-02T20:24:05","guid":{"rendered":"https:\/\/rheumanext.pl\/?page_id=1012"},"modified":"2026-03-02T21:07:16","modified_gmt":"2026-03-02T21:07:16","slug":"biologiczne","status":"publish","type":"page","link":"https:\/\/rheumanext.pl\/en\/kalkulatory\/leczenie\/biologiczne\/","title":{"rendered":"Biologic Therapies (bDMARDs)"},"content":{"rendered":"<p>Monitorowanie bezpiecze\u0144stwa i bada\u0144 kontrolnych przy lekach biologicznych.<\/p>\n\n\n\n<p>This tool is supportive and educational in nature. It does not replace clinical decision-making. <a href=\"https:\/\/rheumanext.pl\/en\/bezpieczenstwo\/\" data-type=\"page\" data-id=\"832\">Zobacz zasady bezpiecze\u0144stwa.<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Lista lek\u00f3w i checklisty<\/h2>\n\n\n<nav class=\"rn-calc-list wp-block-navigation is-layout-flex wp-block-navigation-is-layout-flex\" aria-label=\"Leczenie - biologiczne\"><ul class=\"wp-block-navigation__container  rn-calc-list wp-block-navigation\"><li class=\"wp-block-navigation-item wp-block-navigation-link\"><a class=\"wp-block-navigation-item__content\"  href=\"https:\/\/rheumanext.pl\/en\/leki-biologiczne-inhibitory-ctla-4-abatacept\/\"><span class=\"wp-block-navigation-item__label\">CTLA-4 (Abatacept)<\/span><\/a><\/li><li class=\"wp-block-navigation-item wp-block-navigation-link\"><a class=\"wp-block-navigation-item__content\"  href=\"https:\/\/rheumanext.pl\/en\/leki-biologiczne-inhibitory-il-1-anakinra\/\"><span class=\"wp-block-navigation-item__label\">IL-1 (Anakinra)<\/span><\/a><\/li><li class=\"wp-block-navigation-item wp-block-navigation-link\"><a class=\"wp-block-navigation-item__content\"  href=\"https:\/\/rheumanext.pl\/en\/leki-biologiczne-inhibitory-il-12-23-ustekinumab\/\"><span class=\"wp-block-navigation-item__label\">IL-12\/23 (Ustekinumab)<\/span><\/a><\/li><li class=\"wp-block-navigation-item wp-block-navigation-link\"><a class=\"wp-block-navigation-item__content\"  href=\"https:\/\/rheumanext.pl\/en\/leki-biologiczne-inhibitory-il-23-rizankizumab\/\"><span class=\"wp-block-navigation-item__label\">IL-23 p19 (Rizankizumab)<\/span><\/a><\/li><li class=\"wp-block-navigation-item wp-block-navigation-link\"><a class=\"wp-block-navigation-item__content\"  href=\"https:\/\/rheumanext.pl\/en\/lek-biologiczny-inhibitor-receptora-interferonu-typu-i-anifrolumab\/\"><span class=\"wp-block-navigation-item__label\">IFNAR1 (Anifrolumab)<\/span><\/a><\/li><li class=\"wp-block-navigation-item wp-block-navigation-link\"><a class=\"wp-block-navigation-item__content\"  href=\"https:\/\/rheumanext.pl\/en\/leki-biologiczne-inhibitory-cd20-rytuksymab\/\"><span class=\"wp-block-navigation-item__label\">CD20 (Rytuksymab)<\/span><\/a><\/li><li class=\"wp-block-navigation-item wp-block-navigation-link\"><a class=\"wp-block-navigation-item__content\"  href=\"https:\/\/rheumanext.pl\/en\/leki-biologiczne-inhibitor-baff-belimumab\/\"><span class=\"wp-block-navigation-item__label\">BAFF (Belimumab)<\/span><\/a><\/li><li class=\"wp-block-navigation-item wp-block-navigation-link\"><a class=\"wp-block-navigation-item__content\"  href=\"https:\/\/rheumanext.pl\/en\/leki-biologiczne-inhibitory-anty-tnf-alfa-adalimumab-certolizumab-pegol-golimumab-infliksimab-etanercept\/\"><span class=\"wp-block-navigation-item__label\">anty-TNF (ADA\/CZP\/GOL\/IFX\/ETA)<\/span><\/a><\/li><li class=\"wp-block-navigation-item wp-block-navigation-link\"><a class=\"wp-block-navigation-item__content\"  href=\"https:\/\/rheumanext.pl\/en\/leki-biologiczne-inhibitory-blys-april-atacicept-telitacicept\/\"><span class=\"wp-block-navigation-item__label\">BLyS\/APRIL (Atacicept, Telitacicept)<\/span><\/a><\/li><li class=\"wp-block-navigation-item wp-block-navigation-link\"><a class=\"wp-block-navigation-item__content\"  href=\"https:\/\/rheumanext.pl\/en\/leki-biologiczne-inhibitory-il-17-sekukinumab-ixekizumab\/\"><span class=\"wp-block-navigation-item__label\">IL-17 (Sekukinumab, Iksekizumab)<\/span><\/a><\/li><li class=\"wp-block-navigation-item wp-block-navigation-link\"><a class=\"wp-block-navigation-item__content\"  href=\"https:\/\/rheumanext.pl\/en\/leki-biologiczne-inhibitory-il-6-tocilizumab-sarilumab\/\"><span class=\"wp-block-navigation-item__label\">IL-6 (Tocilizumab, Sarilumab)<\/span><\/a><\/li><li class=\"wp-block-navigation-item wp-block-navigation-link\"><a class=\"wp-block-navigation-item__content\"  href=\"https:\/\/rheumanext.pl\/en\/leki-biologiczne-selektywne-inhibitory-il-23-guselkumab-tildrakizumab\/\"><span class=\"wp-block-navigation-item__label\">IL-23 p19 (GUS\/TIL)<\/span><\/a><\/li><\/ul><\/nav>","protected":false},"excerpt":{"rendered":"<p>Monitorowanie bezpiecze\u0144stwa i bada\u0144 kontrolnych przy lekach biologicznych. Narz\u0119dzie wspieraj\u0105ce i edukacyjne. Nie zast\u0119puje decyzji klinicznych. Zobacz zasady bezpiecze\u0144stwa. Lista lek\u00f3w i checklisty<\/p>","protected":false},"author":1,"featured_media":0,"parent":1008,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"_kadence_starter_templates_imported_post":false,"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"class_list":["post-1012","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/rheumanext.pl\/en\/wp-json\/wp\/v2\/pages\/1012","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rheumanext.pl\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/rheumanext.pl\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/rheumanext.pl\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rheumanext.pl\/en\/wp-json\/wp\/v2\/comments?post=1012"}],"version-history":[{"count":2,"href":"https:\/\/rheumanext.pl\/en\/wp-json\/wp\/v2\/pages\/1012\/revisions"}],"predecessor-version":[{"id":1044,"href":"https:\/\/rheumanext.pl\/en\/wp-json\/wp\/v2\/pages\/1012\/revisions\/1044"}],"up":[{"embeddable":true,"href":"https:\/\/rheumanext.pl\/en\/wp-json\/wp\/v2\/pages\/1008"}],"wp:attachment":[{"href":"https:\/\/rheumanext.pl\/en\/wp-json\/wp\/v2\/media?parent=1012"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}